| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.7 | 0.01 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |